Pfizer is proud of its commitment to advancing hemophilia care for more than 40 years, dating back to the introduction of recombinant therapies. But while there has been transformative progress as well as advances in the hemophilia treatment landscape during this time, there is still work to be done to ensure more patients receive the best care.

Collaboration is an essential component of our efforts to increase access to treatment and bring breakthroughs to people with hemophilia and bleeding disorders all over the world, and initiatives like the World Federation of Hemophilia's (WFH) Twinning Program help make that collaboration possible.

The WFH Twinning Programextlink label, sponsored by Pfizer, fosters partnership and knowledge sharing between hemophilia treatment centers, patient organizations, and youth groups in both established and emerging countries. Through workshops, training sessions, and shared experiences, healthcare professionals in emerging countries have gained access to the latest clinical practices, diagnostic techniques, and treatment protocols. In turn, “twin” organizations in developed nations have gained valuable insights into resource-limited settings.

One of the standout features of the program is its emphasis on capacity building. From 2019 to 2023, the Amman (Jordan) - Dublin (Ireland) Hemophilia Treatment Center (HTC) “twins” conducted numerous training and capacity-building workshops in Amman. These initiatives have significantly improved the capacity for lab diagnosis and led to the opening of another HTC in Zarqa. The Irish team's commitment to enhancing care for people with bleeding disorders in Jordan has been a source of inspiration and motivation for the Jordanian HTC personnel, ultimately reflecting positively on the services and care provided and benefiting those with bleeding disorders.

“We are proud to support the partnerships that emerge from the Twinning Program, but what is most impactful is witnessing the meaningful results that come from these shared experiences,” said Alain Baumann, CEO, World Federation of Hemophilia. “Bringing together the expertise of our partners and seeing a stronger, more connected global bleeding disorders community has been incredibly rewarding.”

Pfizer has long been committed to innovation in hemophilia and is proud to have sponsored the Twinning Program for more than 20 years. In addition to supporting initiatives like the Twinning Program, we are working to advance the treatment paradigm and help people living with hemophilia get the care they need and deserve.

“Our shared goal with the hemophilia community and partners like the World Federation of Hemophilia is to ensure that boundaries – geographical or otherwise – do not limit hemophilia care,” said Ian Winburn, Global Chief Medical Affairs Officer, Pfizer Specialty Care. “We believe we are making important strides to turn this vision into a reality.”